Bertelmann, Thomas

[["dc.bibliographiccitation.firstpage","2271"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Diabetes therapy"],["dc.bibliographiccitation.lastpage","2289"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Ziemssen, Focke"],["dc.contributor.author","Wachtlin, Joachim"],["dc.contributor.author","Kuehlewein, Laura"],["dc.contributor.author","Gamulescu, Maria-Andreea"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Feucht, Nikolaus"],["dc.contributor.author","Voegeler, Jessica"],["dc.contributor.author","Koch, Mirja"],["dc.contributor.author","Liakopoulos, Sandra"],["dc.contributor.author","Schmitz-Valckenberg, Steffen"],["dc.contributor.author","Spital, Georg"],["dc.date.accessioned","2020-12-10T14:14:40Z"],["dc.date.available","2020-12-10T14:14:40Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s13300-018-0513-2"],["dc.identifier.eissn","1869-6961"],["dc.identifier.issn","1869-6953"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15572"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71434"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","7"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Ophthalmology"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Ziemssen, F."],["dc.contributor.author","Feltgen, N."],["dc.contributor.author","Holz, FG."],["dc.contributor.author","Guthoff, R."],["dc.contributor.author","Ringwald, A."],["dc.contributor.author","Bertelmann, T."],["dc.contributor.author","Wiedon, A."],["dc.contributor.author","Korb, C."],["dc.date.accessioned","2019-07-09T11:43:05Z"],["dc.date.available","2019-07-09T11:43:05Z"],["dc.date.issued","2017"],["dc.description.abstract","Abstract Background While randomized controlled trials (RCTs) are based on strict inclusion/exclusion criteria, non-interventional studies (NISs) might provide additional information to guide management in patients more representative to the real-world setting. The aim of this study was to compare baseline characteristics of patients receiving intravitreal treatment in the NIS OCEAN with those from published RCTs. Methods The ongoing OCEAN study enrolled patients treated with ranibizumab for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DME) or branch/central retinal vein occlusion (B/CRVO). Baseline patient characteristics were compared by indication within the OCEAN cohort. Furthermore, the characteristics were set in reference to those of published RCTs in the same indications. Confidence intervals (CIs) were calculated and assessed for statistically significant differences as indicated by non-overlapping CIs. Results Patient characteristics in the NIS OCEAN were evaluated for 3,614 patients with nAMD, 1,211 with DME, 204 with BRVO and 121 with CRVO. Between these groups, significant differences in mean age, gender distributions, and mean baseline VA were seen, reflecting known differences between the indications. Compared to the patient characteristics of published RCTs (trials selected by literature search: nAMD: 13 RCTs, DME: 9, RVO: 5), the OCEAN patients’ mean age was significantly higher in every indication. The gender distributions across the trials were comparable, with only few differences between OCEAN and the RCTs. Regarding the mean baseline VA, notable differences were found in nAMD and in DME, with VA significantly higher in some RCTs and lower in others. Conclusions The described differences underline the complementarity of NISs and RCTs. OCEAN covers a broader spectrum and more variability of patients than do RCTs. As baseline values may have impact on the treatment response (ceiling effect), there is an ongoing need for research in all patient subgroups. Country-specific assessments of patient populations can better reflect the real-world situation. NISs can deliver insights that RCTs may not, as NISs can include non-typical patients, patients with comorbidities, a broader age spectrum and patients of various disease stages. Trial registration The NIS OCEAN was registered on www.clinicaltrials.gov (identifier: NCT02194803 )."],["dc.identifier.doi","10.1186/s12886-017-0401-y"],["dc.identifier.pmid","28103831"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58822"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","BioMed Central"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","132"],["dc.bibliographiccitation.journal","Health and Quality of Life Outcomes"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Scheffler, Martin"],["dc.contributor.author","Hufenbach, Ulrich"],["dc.contributor.author","Wiedon, Annette"],["dc.contributor.author","Wilhelm, Helmut"],["dc.contributor.author","Ziemssen, Focke"],["dc.date.accessioned","2018-11-07T10:08:27Z"],["dc.date.available","2018-11-07T10:08:27Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Vision-related quality of life (vrQoL) is advancing more and more into the focus of interest in ophthalmological clinical research. However, to date only little information is available about vrQoL from large non-interventional studies in terms of \"real-world evidence\". The purpose of this investigation was to describe baseline VFQ-25 visual function scores, to evaluate whether they differ from previous phase III clinical trials, to determine which contributing factors (e.g. indication, age, gender) affect VFQ-25 scores and to identify its impact on driving. Methods: The non-interventional OCEAN study (Observation of treatment patterns with LuCEntis and real life ophthalmic monitoring, including optional OCT in Approved iNdications) is the largest ophthalmic study conducted in Germany, to evaluate the real world situation of patients treated with ranibizumab (NCT02194803). The NEI-VFQ-25 questionnaire was conducted at baseline, months 4, 12 and 24. Descriptive statistics was used to analyse the baseline data. ANOVA was performed to evaluate the impact of various contributing factors on composite and selected subscale scores. Results: Overall, 4844 (84.1 %) of all 5760 OCEAN patients completed the VFQ-25 questionnaire at baseline. Thereof, 3414 treatment-naive patients were further analysed. Overall, the VFQ subscore general health was most affected by the ocular disease, followed by general vision. No major differences were detected in comparison to corresponding VFQ-25 scores of previous phase III clinical trials, except in DME patients, or with respect to possible contributing factors. A tendency towards a more decreased VFQ-25 composite score was observed for nAMD, for elderly patients >= 75 years of age, for female patients, for patients with low baseline visual acuity (VA; <50 letters) and for those with statutory health insurance. Indication, age, gender, baseline VA (all p <0.01) and the interaction of age and indication, as well as baseline VA and indication (p <0.01 each) had a significant impact on composite, general vision and distance vision scores (ANOVA). About 10 % of patients gave up driving due to eyesight issues. Conclusions: The knowledge of a patient's subjective disease burden is crucial to understanding anxieties and mental anguish. Additionally, the understanding of the impact of various contributing factors on the VFQ-25 scores and the extent to which they can be influenced help to optimize patient care. It demonstrates the need for medical and mental support by all medical staff, to encourage patients' compliance with a comprehensive anti-VEGF therapy, to increase BCVA and, consecutively, VFQ-25 scores."],["dc.description.sponsorship","Novartis Pharma GmbH, Germany"],["dc.identifier.doi","10.1186/s12955-016-0536-1"],["dc.identifier.isi","000384693800001"],["dc.identifier.pmid","27644469"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13885"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39464"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1477-7525"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","5815021"],["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Journal of Ophthalmology"],["dc.bibliographiccitation.lastpage","2"],["dc.bibliographiccitation.volume","2017"],["dc.contributor.author","Bertelmann, T."],["dc.contributor.author","Kaymak, H."],["dc.contributor.author","Kretz, F. T. A."],["dc.contributor.author","Koss, M. J."],["dc.date.accessioned","2019-07-09T11:44:46Z"],["dc.date.available","2019-07-09T11:44:46Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1155/2017/5815021"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14898"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59093"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.subject.ddc","610"],["dc.title","Anti-VEGF and Beyond"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","24096"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Berndzen, Lars"],["dc.contributor.author","Raber, Thomas"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Paul, Christoph"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Bemme, Sebastian"],["dc.date.accessioned","2022-01-11T14:08:03Z"],["dc.date.available","2022-01-11T14:08:03Z"],["dc.date.issued","2021"],["dc.description.abstract","The primary objective was to create and establish a new formula that predicts the individual probability of macular hole closure for eyes with full thickness macular holes (FTMH) accompanied by vitreomacular traction (VMT) which received enzymatic vitreolysis using intravitreally administered ocriplasmin. The secondary objective was to evaluate the forecast reliability of a previously published formula for VMT resolution in VMT-only eyes (Odds IVO-Success  = e Intercept  × OR years  × OR ln(µm) ; Probability IVO-Success  = Odds IVO-Success /(Odds IVO-Success  + 1)) on VMT resolution using the current dataset of eyes with FTMH accompanied by VMT. Retrospective analysis of the OASIS, ORBIT, and INJECT-studies. Patients with FTMH and VMT with complete information (n = 213) were included. The effect of gender, age, FTMH diameter, lens status and the presence of epiretinal membranes (ERM) on FTMH closure was assessed using separate univariate logistic regression analyses. With regard to VMT release separate univariate regression analyses were carried out and results were compared with formerly published data of VMT resolution in eyes with VMT only. Overall, 126 eyes (63%) experienced VMT resolution within 28 days. Younger age (p < 0.0001) and VMT diameter (p = 0.041) had a significant impact on VMT release. Overall, 81 eyes (38%) treated with ocriplasmin showed FTMH closure within 28 days. Univariate analysis of the different predictors analyzed revealed that FTMH diameter < 250 µm had a significant impact on treatment success (p = 0.0495). It was not possible to calculate and establish a new multivariate formula that can predict the individual FTMH closure probability for eyes with FTMHs and VMT. However, the results of VMT release prediction in eyes with FTMHs accompanied by VMT matched the prediction of VMT release in eyes with VMT only when using the previously published formula. All in all, predictors for calculating the individual probability of VMT resolution on the one hand and FTMH closure on the other hand are different suggesting diverse pathophysiological mechanisms."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1038/s41598-021-03509-z"],["dc.identifier.pii","3509"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/97924"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-507"],["dc.relation.eissn","2045-2322"],["dc.rights","CC BY 4.0"],["dc.title","Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0181766"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","PloS one"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Callizo, Josep"],["dc.contributor.author","Feltgen, Nicolas"],["dc.contributor.author","Ammermann, Antje"],["dc.contributor.author","Ganser, Janina"],["dc.contributor.author","Bemme, Sebastian"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Pfeiffer, Sebastian"],["dc.contributor.author","Duvinage, Andre"],["dc.contributor.author","Gröschel, Klaus"],["dc.contributor.author","Hoerauf, Hans"],["dc.contributor.author","Wachter, Rolf"],["dc.date.accessioned","2019-07-09T11:43:38Z"],["dc.date.available","2019-07-09T11:43:38Z"],["dc.date.issued","2017"],["dc.description.abstract","BACKGROUND: Patients with retinal vascular occlusion disease have an increased risk for ischemic stroke and share some risk factors with cerebrovascular disease. The purpose of this study was to analyze the prevalence of atrial fibrillation (AF) in subjects with retinal vascular occlusive disease and anterior ischemic optic neuropathy and to compare these data to an ischemic stroke group. METHODS: Prospective, observational single-center trial. Subjects with retinal artery occlusion (RAO), retinal vein occlusion (RVO) and anterior ischemic optic neuropathy (AION) were included. Patients with ischemic stroke (IS) from a previous observational trial were used as control. Investigation included 7-day Holter ECG, echocardiography, duplex ultrasonography of the carotid arteries, and 24-hour blood pressure monitoring. Further vascular risk factors were documented. RESULTS: During the 1-year study period, 101 patients were recruited. The control group with ischemic stroke consisted of 272 subjects. At inclusion, the prevalence of AF was 12% (RAO), 10.2% (RVO), 11.1% (NAION) and 15.8% (IS). The final prevalence after Holter ECG rose to 16% (RAO), 18.4% (RVO), 14.8% (NAION) and 26.5% (IS). No significant difference was measured between groups. CONCLUSIONS: We detected a similar prevalence of AF in all groups. RVO patients tended to exhibit a higher AF detection rate and lower number needed to screen than RAO and NAION. The detection of AF rose considerably via Holter ECG. As a consequence, we recommend prolonged ECG monitoring in patients with acute ophthalmic vascular diseases."],["dc.identifier.doi","10.1371/journal.pone.0181766"],["dc.identifier.pmid","28771491"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14599"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58930"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Atrial fibrillation in retinal vascular occlusion disease and non-arteritic anterior ischemic optic neuropathy."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","974"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Ophthalmic Research"],["dc.bibliographiccitation.lastpage","982"],["dc.bibliographiccitation.volume","64"],["dc.contributor.author","Bertelmann, Thomas"],["dc.contributor.author","Heutelbeck, Astrid"],["dc.contributor.author","Bopp, Silvia"],["dc.contributor.author","Sagebiel, Lise-Lott"],["dc.contributor.author","Eichberg, Silke"],["dc.contributor.author","Hallier, Ernst"],["dc.contributor.author","Hilgers, Reinhard"],["dc.contributor.author","Quiering, Claudia"],["dc.contributor.author","Hoerauf, Hans"],["dc.date.accessioned","2022-01-24T07:03:36Z"],["dc.date.available","2022-01-24T07:03:36Z"],["dc.date.issued","2021"],["dc.description.abstract","The aim of this study was to evaluate the prevalence of back pain among German ophthalmologists, to investigate the relationship towards age, gender, various profession-related factors, to correlate localization of pain to subspecialties, and to explore individual therapeutic and coping strategies."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.1159/000517574"],["dc.identifier.pmid","34348327"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98528"],["dc.language.iso","en"],["dc.relation.eissn","1423-0259"],["dc.relation.issn","0030-3747"],["dc.relation.orgunit","Klinik für Augenheilkunde"],["dc.relation.orgunit","Institut für Medizinische Statistik"],["dc.rights","CC BY-NC 4.0"],["dc.title","Prevalence of Back Pain among German Ophthalmologists"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]